Translumina further strengthens Its technology portfolio with acquisition of Blue Medical Devices, Netherlands

PRNewswire
New Delhi [India]/Helmond [Netherlands], June 29: Translumina, a global leader in Interventional Cardiovascular medical devices with manufacturing presence in Germany and India, today announced the acquisition of Blue Medical Devices, a Wellinq group company, based out of Helmond, Netherlands. The company incorporated in 2013 produces an innovative basket of balloon catheters including Drug Coated Balloons (DCB) and other speciality balloons for complex coronary interventions.
With great excitement, Wellinq's CEO, Sander Hartman, stated: "Becoming part of Translumina, which is an emerging front runner in building a great product- and technology portfolio in coronary and structural heart interventions across the world, marks the beginning of an exciting new chapter for Blue Medical. We are convinced that Blue Medical's next-generation Drug Coated Balloon catheters have a tremendous market opportunity with the global sales and marketing network of Wellinq's long term partner Translumina."
Notably, Blue Medical DCB catheters, Protege NC and Protege SC, significantly overcome the limitations of current DCB technologies and offers high efficacy and safety. The EU-MDR approved DCB catheters have a unique offering of a non-compliant and a semi compliant version. The technology involves a patented drug application technology that prevents any drug loss during the advancement of the device to the lesion resulting in high concentration of the drug at the targeted site.
"This acquisition is of strategic importance as it complements our next generation Drug Eluting Stents portfolio to offer a complete solution for all coronary interventions. Drug Coated Balloons are gaining huge significance in treating certain complex lesion subsets and I am confident that this unique technology will provide new treatment possibilities for physicians and patients worldwide," said Gurmit Singh Chugh who along with Punita Sharma founded Translumina in 2010.
Drug Eluting Balloons are now being considered a treatment of choice for in-stent restenosis, smaller vessels, bifurcations and multivessel disease. The current estimates project DCB market to be almost 30% of the global DES market in the next 5 years.
"I am excited to lead Translumina in this new wave of creating global leadership with path breaking technologies. Our German lineage now makes further inroads in Europe with this move to Netherlands, enabling us to offer a broad range of therapy solutions and disruptive innovations that address the unmet patient needs," said Indranil Mukherjee, Group CEO, Global Business.
The acquisition shall also enable Translumina to use the patented Drug application technology of Blue Medical in other product lines in peripheral and neurovascular interventions complimenting its leadership in unique and innovative dug coating recipes.
"I am overwhelmed with the new realm of opportunities lying ahead for us with this unique DCB technology," commented Paritosh Arora, MD, India.

Arjun Oberoi, Managing Director, Everstone Capital said, "The acquisition of Blue Medical greatly augments our global intervention cardiology portfolio. We are excited to leverage Translumina's global distribution and manufacturing infrastructure to help scale Blue Medical's highly innovative new drug-eluting balloon (Protege) that received EU MDR certification earlier this year."
Incorporated in 2010, Translumina is an interventional cardiovascular device company that delivers world-class products and services. It is a fully integrated product development and manufacturing company with facilities in Germany and India. Over the years, the company has created strategic partnerships with leading hospitals, engineering institutes, global technological companies and renowned interventional cardiologists. Translumina combines the best of German engineering, intellectual property and high-quality standards with India's entrepreneurial culture and strong capabilities in manufacturing innovative products at affordable prices.
For more information, visit

Singapore headquartered Everstone Capital, the private equity arm of the
, is a global firm committed to driving economic growth and creating sustainable value. With seven offices globally (Singapore, Mumbai, Delhi, Gurgaon, Dubai, New York and Mauritius), Everstone Capital focuses on the mid-market with a control mindset and growth bias enabled by an experienced team, comprising best-of-breed investing, operations and strategic resources.
For more information, visit

(Disclaimer: The above press release has been provided by PRNewswire. ANI will not be responsible in any way for the content of the same)